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Abstract
Malnourished HIV-infected patients starting antiretroviral therapy (ART) are at high risk of early mortality, some of which may be attributed to altered
electrolyte metabolism. We used data from a randomised controlled trial of electrolyte-enriched lipid-based nutritional supplements to assess the
association of baseline and time-varying serum phosphate and K concentrations with mortality within the ﬁrst 12 weeks after starting ART. Baseline
phosphate results were available from 1764 patients and there were 9096 subsequent serum phosphate measurements, a median of 6 per patient.
For serum K there were 1701 baseline and 8773 subsequent measures, a median of 6 per patient. Abnormally high or low serum phosphate was
more common than high or low serum K. Controlling for other factors found to affect mortality in this cohort, low phosphate which had not changed
from the previous time interval was associated with increased mortality; the same was not true for high phosphate or for high or low K.
Both increases and decreases in serum electrolytes from the previous time interval were generally associated with increased mortality, particularly in
the electrolyte-supplemented group. The results suggest that changes in serum electrolytes, largely irrespective of the starting point and the direction
of change, were more strongly associated with mortality than were absolute electrolyte levels. Although K and phosphate are required for tissue
deposition during recovery from malnutrition, further studies are needed to determine whether speciﬁc supplements exacerbate physiologically
adverse shifts in electrolyte levels during nutritional rehabilitation of ill malnourished HIV patients.
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The last decade has seen great advances in expanding access to
antiretroviral therapy (ART) for HIV-infected Africans. However,
poor survival in the ﬁrst few months of ART remains a major
concern and undernutrition is a consistent risk factor for this
early mortality(1–4). Malnutrition in these studies has usually been
indicated by low BMI but mortality may result from metabolic
alterations associated with low BMI, not simply from loss of lean
or fat tissue(5). Severe malnutrition is associated with disordered
metabolism of Na, K, P and Mg(6). Low serum phosphate is often
present among malnourished Africans starting ART and is an
independent risk factor for early mortality(7).
We conducted the Nutritional Support for African Adults
Starting Antiretroviral Therapy (NUSTART) trial to test if a high
content of vitamins and minerals in a lipid-based nutritional
supplement (LNS) would decrease mortality of malnourished
adults referred for ART(8). The intervention used a two-stage
dietary protocol based on established methods for managing
malnutrition among young children whereby there is a stabili-
sation phase providing micronutrients and electrolytes but only
modest energy content followed by a rehabilitation phase
with higher energy content in order to permit weight gain(6).
We focused on micronutrients because of their potential beneﬁt
Abbreviations: ART, antiretroviral therapy; DAIDA, Division of AIDS; IQR, interquartile range; LNS, lipid-based nutritional supplement; LNS-VM, lipid-based
nutritional supplements fortiﬁed with vitamins and minerals; NUSTART, Nutritional Support for African Adults Starting Antiretroviral Therapy.
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for HIV patients,(9) and on electrolytes, both because of
their importance in treating malnutrition(6) and because low
phosphate in HIV patients starting ART may be similar to a
potentially dangerous refeeding syndrome(7).
In the NUSTART trial, the addition of a vitamin and mineral
fortiﬁcant to the LNS (LNS-VM) did not decrease mortality within
the ﬁrst 12 weeks of ART compared with the unfortiﬁed LNS but
did result in increases in some anthropometric measures and CD4
count (adjusted improvement of 25 cells/µl)(8,10). The LNS-VM
was also associated with increased incidence of both high
phosphate (>1·45mmol/l; rate ratio (RR) 1·23 compared with
LNS) and high K (>5·5mmol/l; RR 1·6), and decreased incidence
of low phosphate (<0·65mmol/l; RR 0·73)(8). Previous work
from our group has shown increased mortality associated with
low serum phosphate (17% increase/0·1mmol/l increase)(7);
however, analysis of NUSTART patients found signiﬁcant
nonlinear associations between baseline electrolytes and survival
and before starting ART, high, rather than low, phosphate
appeared to carry a greater risk of death(11). In addition, we
observed that the LNS-VM decreased renal wasting of K and
phosphate but not Mg(12). In view of the effects of the LNS-VM
intervention on electrolyte metabolism and on the association of
electrolyte metabolism with mortality, we conducted a secondary
analysis of NUSTART data. We performed detailed time course
analysis of the effects of the intervention and its associated
time-varying consequences on electrolyte levels and on the
changes in electrolyte levels in relation to mortality in the trial.
Methods
Study design and intervention
NUSTART was an individually randomised, controlled, two-site,
two-arm, phase III trial comparing LNS (Nutriset) either with
(LNS-VM) or without (LNS) high levels of vitamins and minerals
among participants who were HIV-positive and malnourished.
The trial design, detailed intervention and primary ﬁndings
have been reported previously(8). The intervention was
given at two graduated energetic doses mimicking nutritional
management of malnourished children(6); daily vitamin and
mineral doses were the same in both the low-energy period
given from referral to ART until 2 weeks after starting ART and
the higher energy period given from weeks 2 to 6 of ART.
Follow-up without supplementation continued until week 12 of
ART. Varying actual ART start dates resulted in varied pre-ART
durations of LNS or LNS-VM consumption with the median
and mode being 3 weeks. The daily phosphate intake from
the fortiﬁed LNS-VM was 38–47mmol (according to the
manufacturer’s analyses; the range is due to variability in
product batches); for comparison, the UK upper reference
nutrient intake (RNI) is 17·5mmol/d for adults(13). The daily K
intake from LNS-VM was 30–32mmol; the UK RNI for adults is
90mmol/d. The trial was registered at PACTR201106000300631.
Setting and participants
The trial was conducted between August 2011 and December
2013 at the National Institute for Medical Research (NIMR),
Mwanza, Tanzania and the University Teaching Hospital, Lusaka,
Zambia. Participants were recruited from HIV clinics near the two
trial sites. Eligible participants had BMI <18·5kg/m2, were ART
naive (except for previous short course regimens used to prevent
mother to child HIV transmission), needed to start ART as
determined by CD4 count <350 cells/μl or WHO stage 3 or 4(14),
were at least 18 years old, willing to undertake intensive follow-up
in the study clinics, and providing informed consent. Participants
were ineligible if participating in a potentially conﬂicting research
study or self-reported a pregnancy.
Randomisation and masking
The statistician member of the independent data safety and
monitoring committee generated the randomisation list. The list
was computer generated in blocks of sixteen and stratiﬁed by
country. Clinic pharmacists labelled the packets of LNS-VM and
LNS with study ID numbers as packages were dispensed. Clinic
nurses who were blinded to the randomisation list assigned
sequential (within site) ID numbers.
Follow-up and data management
Patients were seen weekly from recruitment until the ART
initiation visit, then at 2, 4, 6, 8, and 12 weeks after starting ART.
Participants could also come for unscheduled visits at any time.
At each visit, including unscheduled ones, medical and
other examinations were conducted(8) and blood samples were
collected for electrolyte assays. For ethical reasons, we provided
speciﬁc electrolyte supplements to participants with low
electrolyte values. Phosphate tablets (97mmol/d for 7 d) were
supplied to thirty-seven participants and K tablets (48mmol/d for
7 d) to nine participants. One participant in Lusaka received
intravenous K (40mmol over 8 h).
Laboratory analysis
In Lusaka serum phosphate was measured spectrochemically
on a Pointe 180 analyser (Pointe Scientiﬁc). Sample results were
accepted only from runs for which the external quality control
(QC) sample from the same supplier was within expected
range; for unacceptable runs, samples were reanalysed where
possible or omitted if not. Inter-assay CV for this external QC
was 7%. In Mwanza serum phosphate was measured in an
external laboratory (Bugando Medical Centre) using a Roche
COBAS Integra 400 analyser (Roche Molecular Diagnostics).
Serum K was measured by optical emission using Perkin Elmer
Optima 7000 ICP (Perkin Elmer). An external QC (Seronorm;
Alere) was run each day and values were within expected limits
at both sites. Inter-assay CV for K were 5% in Mwanza and 6%
in Lusaka.
Cut-offs for low (<0·65mmol/l) serum phosphate and low
(<2·5mmol/l) or high (>6·5mmol/l) serum K levels were set
according to the US National Institutes of Health, Division of
AIDS (DAIDS(15)) grades 3 and 4. DAIDS does not set high
ranges for phosphate so we considered as above normal limits
if >1·45mmol/l and below normal limits if <0·87mmol/l(16); for
comparison we also looked at any K above, >5·5mmol/l, or
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below, <3·5mmol/l, normal limits(16) which were equivalent to
grades 1 or 2 DAIDS.
Statistical analysis and outcomes
Data were double entered into OpenClinica data management
system in Lusaka and into CSPro 4.1 and stored in MySQL
databases in Mwanza. Analyses were conducted in STATA
version 14.1.
Electrolyte levels at the end of follow-up (12 weeks
post-ART) were analysed as continuous variables. Means were
compared between treatment arms using t tests and linear
regression adjusting for baseline values. Comparisons at the end
of follow-up, by deﬁnition, used the subset of patients who
survived and attended the 12-week visit within 14 d of the
scheduled date (i.e. up to 14 weeks post-ART) as decided
a priori. However, we also wanted to investigate treatment
effects using all measured data, including data from patients
who died or were lost to follow-up until the point they were
lost from the study. We used piecewise mixed-effects cubic
regression models with the time axis split at the date of starting
ART. Random intercepts and random linear slopes were
incorporated into the model. This model ﬁtted two lines per
person with differing slopes, restricting the lines to join at the
date of starting ART. P values provide evidence of whether the
shape of curves differed by treatment arm. For presentation,
marginal predictions are graphed and are based on the median
time, 21 d, spent before starting ART.
Knowing that LNS-VM was associated with increased
incidence of high electrolyte values, and that risk of death
before starting ART appeared higher with increasing levels of
baseline serum phosphate(11), we sought to examine the effect
of the intervention on mortality allowing for the time-varying
measurements of electrolyte values. Time was split into 4-week
bands and also split pre- and post-starting ART, and controlled
for in the analysis. Participants with electrolytes measured only
once (n 156 for phosphate; n 104 for K) were excluded because
time changes could not be determined, and those missing ART
start date (n 31) were excluded from analysis because the split
could not be performed. Participants were censored at
14 weeks after starting ART, at their last visit if they were lost to
follow-up or withdrew, or at 10 weeks after recruitment for the
114 participants who had not yet started ART by this point. We
used time-to-event shared frailty Poisson regression models to
estimate the effect of treatment arm on mortality using hazard
ratios, both unadjusted and adjusted for factors associated
with mortality. The current (and time changing) value of the
electrolyte was categorised into tertiles of high, middle or low.
Standardised changes from the previous value, to control for
varying intervals between visits, were categorised into increase,
no change or decrease; for K increase or decrease was deﬁned
as >0·03mmol/d and for phosphate it was deﬁned as
>0·02mmol/d. These two variables were incorporated into
models as main effects and additionally tested for interaction.
When interaction was present, current level and change from
previous level were combined to form a categorical variable
with nine levels. In either case, these variables were allowed to
vary over time in the model.
Sample size
Recruitment to the trial was stopped early, following advice
from the trial Data Safety and Monitoring Board, because a
higher than expected mortality rate (not related to the inter-
vention) meant we already had sufﬁcient power for the primary
outcome of mortality(8). The 1815 participants who were
enrolled in the trial gave 90% power to detect a difference of
30% between trial arms in the primary outcome of mortality.
The 800 participants with electrolyte values measured at
12 weeks after initiating ART gave 80% power to detect a
difference of 0·20mmol/l between trial arms.
Ethics
The study was conducted according to the guidelines laid down
in the Declaration of Helsinki and all procedures involving
human participants were approved by the ethics committee
of the London School of Hygiene and Tropical Medicine, the
Medical Research coordinating committee of NIMR, Tanzania
and the University of Zambia Biomedical Research Ethics
Committee. Written or thumbprint consent was obtained from
all participants. Patients received medical care from local health
services according to national guidelines.
Results
Participants were comparable at baseline between trial arms
(Table 1 for participants with phosphate data and the online
Supplementary Table S1 for the slightly different number of
participants with K data). Of 1815 participants, 1764 (97%) had
baseline serum phosphate data and 1710 (94%) had baseline K
data (Table 2). Phosphate at baseline was above normal levels
(>1·45mmol/l) in one-ﬁfth of participants and below normal
(<0·87mmol/l) in 14%; K was above normal levels (>5·5mmol/l)
in 3% and below normal (<3·5mmol/l) in 15% of participants
(Table 2). Only 3·4% had low levels of both K (<3·5mmol/l) and
phosphate (<0·87mmol/l) at baseline.
Up to 14 weeks after starting ART, there were 9096
subsequent phosphate results in 1608 participants, median 6
(interquartile range (IQR) 3–8) per patient, and 8773 subsequent
K results in 1606 participants, median 6 (IQR 3–7) per patient,
with comparable numbers of observations in each trial arm.
Above normal phosphate (>1·45mmol/l) was the most
commonly occurring abnormal electrolyte result (Table 3).
Episodes of above normal phosphate measured on consecutive
occasions, that is weekly, every 2 or every 4 weeks, depending
on the time before or after starting ART, occurred in 368 (204
from LNS-VM arm) participants for a median episode length of
14 (IQR 7–28) d. Episodes of low phosphate (<0·65mmol/l;
DAIDS grades 3 and 4) measured on consecutive occasions
occurred in twenty-eight participants for a median episode
length of 14 (IQR 7–17·5) d. There were no occasions where
high K (>6·5mmol/l; DAIDS grades 3 and 4) was measured on
consecutive occasions. Seven participants experienced episodes
of K remaining above normal, 5·5mmol/l (equivalent to DAIDS
grades 1 and 2), for a median of 7 (IQR 7–14) d and eleven
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participants had low K (<2·5mmol/l; DAIDS grades 3 and 4) for
a median of 14 (IQR 7–38) d.
At the end of follow-up, 6 weeks after discontinuation of
the study supplement, there was no evidence of a difference
between trial arms in mean serum phosphate (overall mean 1·25
(SD 0·35)mmol/l), adjusted difference 0·03 (95% CI −0·02,
0·08, P=0·24, n 798) or mean serum K (overall mean 4·13
(SD 0·64)mmol/l), adjusted difference 0·002 (95% CI −0·10, 0·10,
P=0·97, n 754). Participants who had remained in the study and
had electrolytes measured at the end of follow-up were older,
more likely to be female, be on tuberculosis treatment at baseline,
had higher socio-economic status, higher baseline BMI, higher
baseline CD4 count and were less likely to be divorced; for having
a phosphate measurement they were also more likely to be
Zambian (online Supplementary Tables S2 and S3).
Fig. 1 shows electrolyte changes over time for patients who
started ART at the median of 3 weeks after referral for treatment.
Similar ﬁgures for participants who survived until the end of the
study are shown in the online Supplementary Fig. S1 and S2,
and for those starting ART 1, 2 or 4 weeks after referral are
shown in the online Supplementary Fig. S3 and S4. There was
strong evidence that changes in phosphate and K over time
differed by trial arm; P values for differences between LNS and
LNS-VM groups for both K and phosphate were 0·0002 overall
and differences in the pre- and post-ART time periods were
also highly signiﬁcant (Fig. 1). In the LNS-VM arm values of
electrolytes were found on average to increase up to the time
ART started and then reduce to baseline levels by the end of
follow-up whereas in the LNS arm average values changed little
over follow-up time.
Mortality was higher among males, Tanzanians, those with
oedema at baseline, those not on tuberculosis medication at
baseline, and increased with age, with higher C-reactive protein
(CRP), with lower CD4 cell count and with lower BMI at baseline
(data presented by Woodd et al.(11)). The current value of plasma
electrolyte and the change from the previous value showed
signiﬁcant interaction for phosphate analyses so the nine level
categorical analysis is presented; these interactions were not
signiﬁcant for K, so main effects are presented (Table 4).
Once adjusted for factors associated with mortality, there was
some evidence overall (P= 0·03, phosphate, P= 0·06 K) that
time-varying electrolytes affected mortality (Table 4, n 9027
phosphate measurements on 1588 participants, n 8709 K
measurements on 1588 participants; median number of
measurements in those dying was 3 (IQR 2, 5) and in those
completing follow-up was 8 (IQR 6, 9)). Compared with
participants with stable measurements around the mean,
participants with electrolyte values which were not stable, had
increased hazard of mortality (Table 4). Although there was no
evidence that the effect of serum electrolytes was modiﬁed by
trial arm (Pfor interaction> 0·34), due to the LNS-VM arm containing
electrolytes by design, we a priori also examined the effect
Table 1. Baseline characteristics of patients included in the evaluation of
the effect of Nutritional Support for African Adults Starting Antiretroviral
Therapy intervention on serum phosphate
(Numbers and percentages; mean values and standard deviations)
LNS (n 883) LNS-VM (n 898)
n % n %
Age (years)
Mean 35·8 35·9
SD 9·44 9·33
Female 445 50·4 437 48·7
On tuberculosis treatment* 129 14·6 173 19·3
Baseline CD4 count (cells/µl)
Mean 140·0 135·6
SD 103·3 96·7
CD4 count <100 (cells/µl) 383 43·4 385 42·9
BMI <17 (kg/m2) 523 59·2 528 58·8
Social economic status
Lowest 193 21·9 166 18·5
Low 184 20·8 181 20·2
Middle 160 18·1 194 21·6
High 180 20·4 170 18·9
Highest 166 18·8 187 20·8
Marital status*
Married 430 48·7 411 45·8
Widow/widower 104 11·8 95 10·6
Divorced/separated 237 26·8 261 29·1
Single 108 12·2 129 14·4
Lives with partner 3 0·3 2 0·2
Occupation*
Salaried 135 15·3 130 14·5
Self-employed 454 51·4 475 52·9
Housewife 93 10·5 84 9·4
Student 9 1·0 9 1·0
Unemployed 191 21·6 200 22·3
Education level*
None 167 18·9 168 18·7
Primary 508 57·5 518 57·7
Secondary 184 20·8 188 20·9
University/tertiary 23 2·6 24 2·7
Study site
Lusaka 540 61·2 552 61·5
Mwanza 343 38·8 346 38·5
LNS, lipid-based nutritional supplement; LNS-VM, lipid-based nutritional supplement
with added vitamins and minerals.
* Missing values for: on tuberculosis treatment, 7 (0·8%) LNS arm, 6 (0·7%) LNS-VM
arm; marital status: 1 (0·1%) LNS arm; occupation: 1 (0·1%) LNS arm; education
level: 1 (0·1%) LNS arm.
Table 2. Serum phosphate and potassium values at baseline among
patients randomised to lipid-based nutritional supplement (LNS) or lipid-based
nutritional supplement with added vitamins and minerals (LNS-VM)
(Mean values and standard deviations; numbers and percentages)
LNS-VM LNS
n* % n* %
Serum phosphate (mmol/l) 888 876
Mean 1·24 1·24
SD 0·41 0·37
<0·65mmol/l† 27 3 24 3
<0·87mmol/l‡ 113 12 83 9
>1·45mmol/l‡ 177 20 169 19
Missing 26 3 25 3
Serum K (mmol/l) 861 849
Mean 4·14 4·09
SD 0·73 0·72
<2·5mmol/l† 10 1 14 2
<3·5mmol/l‡ 133 15 141 16
>5·5mmol/l‡ 27 3 16 2
>6·5mmol/l† 7 0·8 2 0·2
Missing 53 6 52 6
* Total enrolled in the trial were: LNS-VM arm, n 914; LNS arm, n 901.
† Values from Division of AIDS grades 3 or 4 adverse events(15).
‡ Values below or above normal range(16).
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of changes in electrolytes stratiﬁed by trial arm (online
Supplementary Tables S4(a) and (b)); the estimates were
comparable to those in Table 4. The effect of changes in
phosphate was statistically signiﬁcant in both arms, but the
magnitudes of the adjusted hazard ratios tended to be greater in
the LNS-VM than in the LNS arm. It should be noted that the
intervention had no overall effect on mortality(8) and that
the number of deaths in some electrolyte groups was small in
these analyses of separate trial arms.
Discussion
Our previous analysis of baseline serum electrolyte data and
subsequent mortality in the malnourished NUSTART cohort(11)
showed no signiﬁcant effects of baseline serum phosphate or K
on mortality to 12 weeks after starting ART but this ﬁnding
differed from the signiﬁcant mortality risk of low phosphate at
start of ART reported in a similar cohort of malnourished
Zambians starting ART(7). Given these conﬂicting ﬁndings
regarding electrolyte levels at the time of treatment initiation, the
present analysis extends these ﬁndings to time intervals both
before and after starting ART in order to give a fuller picture of the
dynamic situation in which serum electrolytes change over time
under the inﬂuence of several factors: diet, tissue catabolism or
anabolism, ART and renal function. The values in the LNS group
may reﬂect the usual situation without provision of high levels of
vitamins and minerals since, even though LNS is not usually
given, food intake increases as health and appetite improve
with ART(17). The LNS-VM group shows the added effect of
providing vitamins and minerals. High levels of serum K were
uncommon at both baseline and during the intervention whereas
high phosphate was common throughout, especially in the LNS-
VM group. The level of phosphate in the LNS-VM preparation
was about twice the RNI and much lower than the tolerable
upper level(13). Therefore the high incidence of above-normal
serum phosphate suggests that malnourished, HIV-infected adults
have much lower metabolic capacity to handle this electrolyte
than do healthy individuals. In a small subset of the NUSTART
Lusaka patients we did ﬁnd evidence of abnormal renal wasting
of electrolytes which was improved in the LNS-VM group by
week 12(12). Renal wasting of electrolytes would be expected to
result in abnormally low, not high electrolytes. Unfortunately, we
do not have data on renal electrolyte handling at any time points
between baseline and 12 weeks ART.
Important questions are whether transient changes in serum
electrolytes resulted in any adverse effects to the patients and
whether relatively high intakes of electrolytes affected the number
of adverse events. The results suggest that changes in serum
electrolytes between visits, largely irrespective of the starting point
and the direction of change, were more strongly associated
with mortality than were absolute electrolyte levels. The changes
appeared to have their greatest effects for phosphate, and high
supplementary amounts of electrolytes through LNS-VM treatment
may have accentuated the effects. Labile serum electrolyte
levels support the idea of poor metabolic control among
this malnourished population with advanced HIV, and high
Table 3. Abnormal serum electrolyte values over the study period by trial arm and total in study
(Numbers of measurements (Nm) and number of participants (Np))
Pre-ART* Post-ART
Total Post baseline to 21 d >21 d ART to 14 d after ART 15–42 d after ART 43–98 d after ART†
Adverse event or abnormality Nm Np Nm Np Nm Np Nm Np Nm Np Nm Np
Phosphate <0·65mmol/l‡
LNS-VM 106 87 17 14 7 6 22 17 30 25 30 24
LNS 137 113 42 37 3 3 42 31 28 24 23 18
Phosphate >1·45mmol/l§
LNS-VM 1081 514 353 194 89 28 207 111 204 85 228 96
LNS 834 432 227 130 65 25 142 69 177 86 223 122
n in study
LNS-VM 4717 816 1285 716 389 218 980 623 1008 569 1055 525
LNS 4379 792 1232 701 284 170 971 598 935 538 957 491
K <2·5mmol/l‡
LNS-VM 38 28 9 7 8 4 7 5 7 5 7 7
LNS 43 36 17 15 3 2 7 5 8 8 8 6
K >6·5mmol/l‡
LNS-VM 33 32 8 8 4 3 9 9 5 5 7 7
LNS 19 19 5 5 2 2 5 5 1 1 6 6
K >5·5mmol/l‡
LNS-VM 132 114 50 44 15 11 29 26 19 17 19 16
LNS 77 71 30 30 11 8 13 12 10 10 13 11
n in study
LNS-VM 4542 811 1249 704 368 213 949 597 979 557 997 523
LNS 4231 795 1203 693 271 166 939 578 908 526 910 487
ART, antiretroviral therapy; LNS, lipid-based nutritional supplement; LNS-VM, lipid-based nutritional supplements fortified with vitamins and minerals.
* Individuals varied in the time spent in the pre-ART period, median 3 (interquartile range 2·1–4·7) weeks.
† This period was after supplementation ended.
‡ Division of AIDS grades 3 or 4(15).
§ Above normal limits(16).
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supplementary electrolytes may further impair this control. The
lack of association between serum K and mortality may appear
surprising. We were able to examine only the effect (and showed
no association) of above average values, as the number of patients
with abnormal, and in particular extremely abnormal values
was low.
The study has several limitations. We are unable to comment on
additional dietary sources of electrolytes as detailed dietary intakes
were not measured in the trial. In addition, levels of phosphate in
the supplements were analysed by the manufacturer which is a
potential limitation, although likely not a large one as the two
supplements were clearly different and the focus of the study was
on patient metabolism, not intake. Although randomisation and a
large sample size should have ensured balance between trial arms
and reduced potential effects of residual confounding, in this
observational investigation we cannot estimate causal associations
between serum electrolyte levels and mortality. It is possible that
electrolyte changes could also be a consequence of illness which
leads to increased mortality through another causal pathway. We
adjusted for illness, as measured by serum CRP and tuberculosis
infection (treatment), although we know that some mortality could
be partially explained by undiagnosed tuberculosis infection
among other causes. In addition, by including electrolyte levels as
a time-varying confounder we are making the assumption that the
effect of electrolytes on mortality is not modiﬁed by follow-up
time. An alternative formulation to investigate for time-modiﬁed
confounding could be structural equation models. As our follow-
up time was relatively short, our assumption, and simpler model,
should be adequate. Finally, we were unable to assess for
any time-varying inﬂuence of CD4 cell count as this was only
measured at baseline and end of study which, if it inﬂuenced the
relationship between electrolyte levels and mortality, could
increase the potential for residual confounding.
The main strength of our study was the large longitudinal
sample size of serum electrolyte values which were repeated
at fairly regular intervals, weekly or fortnightly for most parti-
cipants. In addition, being able to compare within participants
from referral until after ART commenced provided valuable and
clinically relevant information on changes over time. We,
however, cannot rule out that visit frequency and timing could
have been related in part to participant health, with both
increases in frequency (unscheduled visits and extra serum
testing due to illness) and decreases in frequency (very ill
leading to death) occurring because of ill health. Given the
large sample size, we would envisage that the results are robust
enough to any form of systematic bias. We have chosen to
present results combined over intervention groups partly
because the intervention did not signiﬁcantly affect mortality,
but also because we know that participant adherence to
supplements was on the low side, with only 39% of participants
consuming at least 75% of their LNS sachets, thus reducing
differences in electrolyte intake(8). As we were not able to
tell if adherence changed when the energetic dose increased
at 2 weeks from ART initiation, we are not able to infer
if the decrease in serum electrolyte levels post-ART could
be partially explained by decreased dosing if participants
were unable to consume all of their LNS at the higher
energy level or if it was truly due to metabolic stabilisation or
commencing ART.
Low serum phosphate is commonly seen in malnourished
patients, both with and without HIV infection, and is associated
with poor outcomes(7,18,19). Our analyses focused on electrolyte
metabolism, not dietary intake other than the differences
between the LNS and LNS-VM preparations. However, dietary
management of these patients remains critical and the amounts
of phosphate and other electrolytes which should be provided
in therapeutic diets for malnourished people in order to restore
metabolic stability, increase tissue deposition and avoid
the refeeding syndrome or other adverse effects is still under
research(19). Based on our results, we recommend that future
interventions to improve nutritional status of malnourished
HIV-infected patients should not include high doses of
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Fig. 1. Changes in predicted mean serum electrolytes over time by trial arm,
for an individual who started antiretroviral therapy (ART) 3 weeks after
recruitment. (a) Phosphate: P values for differences between lipid-based
nutritional supplement (LNS) and lipid-based nutritional supplements fortified
with vitamins and minerals (LNS-VM) groups were 0·0002 overall, 0·008 pre-
ART and 0·0003 post-ART. Curves represent marginal predictions based on all
available data for all patients and are derived from piecewise cubic equations
with random slopes and intercepts. Prediction equations have different slopes
pre- and post-starting ART. (b) K: P values for differences between LNS and
LNS-VM groups were 0·0002 overall, 0·0002 pre-ART and 0·004 post-ART.
Curves represent marginal predictions based on all available data for all
patients and are derived from piecewise cubic equations with random slopes
and intercepts. Prediction equations have different slopes pre- and post-
starting ART. , LNS; , LNS-VM.
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Table 4. Poisson regression models for time-varying serum electrolyte values associated with mortality between referral for antiretroviral therapy (ART) and ART initiation
(Unadjusted and adjusted hazard ratios (HR) and 95% confidence intervals)
Change from
Mortality rate/
100 person-years
Current values* previous value† Deaths (n) 100 person-years HR‡ 95% CI Unadjusted HR‡ 95% CI P Adjusted HR§ 95% CI P
Phosphate||
Low Decrease 24 0·34 70 47, 105 3·59 2·15, 5·98 1·93 1·13, 3·32
Low No change 20 0·48 42 27, 65 1·82 1·06, 3·14 1·79 1·01, 3·17
Low Increase 4 0·02 180 68, 481 13·01 4·60, 36·75 7·09 2·34, 21·54
Middle Decrease 31 0·35 89 63, 127 4·89 3·04, 7·88 2·80 1·69, 4·67
Middle No change 38 1·67 23 17, 31 Ref. <0·001 Ref. <0·001
Middle Increase 27 0·28 98 67, 142 4·65 2·82, 7·69 2·62 1·53, 4·49
High Decrease 5 0·05 107 45, 258 4·55 1·77, 11·65 3·75 1·39, 10·12
High No change 14 0·42 33 20, 56 1·43 0·78, 2·65 1·34 0·69, 2·61
High Increase 28 0·39 72 50, 104 3·27 2·00, 5·35 1·99 1·18, 3·35
K¶
Low – 93 0·91 102 83, 125 2·09 1·55, 2·83 1·26 0·92, 1·73
Middle – 104 2·80 37 31, 45 Ref. <0·001 Ref. 0·20
High – 53 0·79 67 52, 88 1·52 1·06, 2·17 1·32 0·91, 1·92
– Decrease 97 0·94 103 84, 126 2·72 1·98, 3·74 1·48 1·06, 2·07
– No change 78 2·60 30 24, 37 Ref. <0·001 Ref. 0·06
– Increase 73 0·91 81 64, 101 2·36 1·67, 3·34 1·30 0·92, 1·85
Ref., referent values.
* For phosphate low is 0·04–0·96, middle is 0·97–1·44, high is 1·45–5·27. For K low is 0·1–3·63, middle is 3·63–4·5 and high is 4·6–10mmol/l.
† For serum phosphate daily changes were defined as: <−0·02 a decrease, (−0·02, 0·02) no change and >0·02 increase· For K daily changes were defined as <−0·03 a decrease, (−0·03, 0·03) no change and >0·03 an increase.
‡ A Lexis expansion for time was adjusted for in 4-week time bands, both pre-art and post-art. Being on ART was also adjusted for.
§ Adjusted for trial arm (lipid-based nutritional supplement or lipid-based nutritional supplements fortified with vitamins and minerals), time band (as for ‡), country, sex, age group (18–29, 30–39, 40–49, ≥50 years), baseline CD4 count
(<50, 50–99, 100–199, ≥200 cells/μl), BMI (continuous), baseline tuberculosis treatment (yes/no), baseline oedema (yes/no), baseline C-reactive protein (<10, 10–49, 50–159, ≥160mg/l).
|| Pfor interaction value between current level and change from previous level unadjusted model= 0·03, adjusted model=0·03.
¶ Pfor interaction value between current level and change from previous level unadjusted model=0·85, adjusted model =0·47.
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electrolytes early after starting ART as malnourished HIV patients
appear unable to handle electrolytes, particularly phosphate,
adequately. Once metabolism is stabilised and health improves,
both K and phosphate are needed for tissue deposition so should
be provided in adequate amounts.
Acknowledgements
The authors are grateful to the large clinical, laboratory and
data teams involved in the NUSTART trial in both Mwanza and
Lusaka and to the study participants who donated their time and
samples.
This study was funded by European and Developing Coun-
tries Clinical Trials Partnership grant no. IP.2009.33011.004; trial
foods were prepared and supplied by Nutriset, Malauney,
France. Salary support for A. M. R. was provided by the Medical
Research Council (MRC) Tropical Epidemiology Group
jointly funded under grant no. MR/K012126/1 by the UK
MRC and the UK Department for International Development
(DFID) under the MRC/DFID Concordat agreement and is
also part of the EDCTP2 programme supported by the
European Union. None of the funders had any role in the
design, conduct or interpretation of the study and decision
to publish results.
A. M. R. conducted the statistical analyses with input from
S. L. W. S. F. drafted the manuscript and was principal investigator
for the NUSTART trial. D. C. H., J. R. K., H. F., G. P., L. K. and
P. K. were involved in the design and interpretation of the
NUSTART trial including the component in this manuscript.
All authors approved the ﬁnal manuscript.
The authors declare that there are no conﬂicts of interest.
Supplementary material
For supplementary material/s referred to in this article, please
visit https://doi.org/10.1017/S0007114517000721
References
1. Liu E, Spiegelman D, Semu H, et al. (2011) Nutritional
status and mortality among HIV-infected patients
receiving antiretroviral therapy in Tanzania. J Infect Dis 204,
282–290.
2. Koethe JR, Lukusa A, Giganti MJ, et al. (2010) Association
between weight gain and clinical outcomes among malnourished
adults initiating antiretroviral therapy in Lusaka, Zambia. J Acquir
Immune Deﬁc Syndr 53, 507–513.
3. Gupta A, Nadkarni G, Yang WT, et al. (2011) Early mortality
in adults initiating antiretroviral therapy (ART) in low- and
middle-income countries (LMIC): a systematic review and
meta-analysis. PLoS ONE 6, e28691.
4. Lawn SD, Harries AD, Anglaret X, et al. (2008) Early mortality
among adults accessing antiretroviral treatment programmes
in sub-Saharan Africa. AIDS 22, 1897–1908.
5. Dao CN, Peters PJ, Kiarie JN, et al. (2011) Hyponatremia,
hypochloremia, and hypoalbuminemia predict an increased
risk of mortality during the ﬁrst year of antiretroviral therapy
among HIV-infected Zambian and Kenyan women. AIDS Res
Hum Retroviruses 27, 1149–1155.
6. Ashworth A, Khanum S, Jackson A, et al. (2003) Guidelines
for the inpatient treatment of severely malnourished children.
http://www.who.int/nutrition/publications/guide_inpatient_text.
pdf
7. Heimburger DC, Koethe JR, et al. (2010) Serum phosphate
predicts early mortality in adults starting antiretroviral therapy
in Lusaka, Zambia: a prospective cohort study. PLoS ONE 5,
e10687.
8. Filteau S, PrayGod G, Kasonka L, et al. (2015) Effects on
mortality of a nutritional intervention for malnourished HIV-
infected adults referred for antiretroviral therapy: a randomised
controlled trial. BMC Med 13, 17.
9. Friis H (2006) Micronutrient interventions and HIV infection: a
review of current evidence. Trop Med Int Health 11, 1849–1857.
10. Rehman AM, Woodd S, et al. (2015) Effects on anthropometry
and appetite of vitamins and minerals given in lipid nutritional
supplements for malnourished HIV-infected adults referred
for antiretroviral therapy: results from the NUSTART rando-
mized controlled trial. J Acquir Immune Deﬁc Syndr 68,
405–412.
11. Woodd S, Kelly P, Koethe JR, et al. (2016) Risk factors for
mortality among malnourished HIV-infected adults eligible for
antiretroviral therapy. BMC Infect Dis 16, 562.
12. Munkombwe D, Muungo TL, Michelo C, et al. (2016) Lipid-
based nutrient supplements containing vitamins and minerals
attenuate renal electrolyte loss in HIV/AIDS patients starting
antiretroviral therapy: a randomized controlled trial in Zambia.
Clinical Nutrition ESPEN 13, e8–e14.
13. UK Department of Health (1991) Dietary Reference Values for
Food Energy and Nutrients for the UK. London: Department of
Health.
14. World Health Organization (2007) WHO Case Deﬁnitions of
HIV for Surveillance and Revised Clinical Staging and
Immunological Classiﬁcation of HIV-Related Disease in
Adults and Children. Geneva: WHO. http://www.who.int/
hiv/pub/guidelines/HIVstaging150307.pdf
15. UC Davis Clinical Trials Ofﬁce (2004) Division of AIDS
table for grading the severity of adult and pediatric
adverse events. http://ucdmc.ucdavis.edu/clinicaltrials/Study
Tools/Documents/DAIDS_AE_GradingTable_FinalDec2004.pdf
(accessed November 2010).
16. Tietz N (1995) Clinical Guide to Laboratory Tests, 3rd ed.
London: WB Saunders.
17. Koethe JR, Blevins M, Bosire C, et al. (2013) Self-reported dietary
intake and appetite predict early treatment outcome among
low-BMI adults initiating HIV treatment in sub-Saharan Africa.
Public Health Nutr 16, 549–558.
18. Golden M (2009) Proposed recommended nutrient densities
for moderately malnourished children. Food Nutr Bull 30,
S267–S342.
19. Namusoke H, Hother AL, Rytter MJ, et al. (2016) Changes in
plasma phosphate during in-patient treatment of children with
severe acute malnutrition: an observational study in Uganda.
Am J Clin Nutr 103, 551–558.
Serum electrolytes in African HIV patients 821
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114517000721
Downloaded from https:/www.cambridge.org/core. London School of Hygiene & Tropical Medicine, on 02 May 2017 at 20:24:14, subject to the Cambridge Core terms of use, available at
